Pharma Firm General Counsel on How Risk, Flexibility Delivered 'Home Run' With COVID-19 Drug

May 2020

Hayden Trubitt, a shareholder in Stradling’s Corporate practice group, was quoted in an article published by Law.com, “Pharma Firm General Counsel on How Risk, Flexibility Delivered 'Home Run' With COVID-19 Drug.” Hayden represented Ligand Pharmaceuticals in its $35.5 million acquisition of CyDex Pharmaceuticals Inc. in 2011. CyDex holds the license for Captisol, a crucial ingredient in COVID-19 treatment drug remdesivir. He was also involved in Ligand’s licensing and supply agreement with Gilead. “It’s understood when you build a company with literally hundreds of shots on goal that most of them will be either zeros or not much. But a few will be home runs,” Trubitt said. “It’s an interesting business model and that’s how the company plays its game.”

Read the full article here.

Please enable JavaScript, then refresh this page. JavaScript is required on this site.